Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Timolumab - Acorda Therapeutics

Next Previous
X
Search
Drug Profile

Timolumab - Acorda Therapeutics

Alternative Names: Anti-VAP-1 monoclonal antibody fully human; BTT-1023; Fully human anti-VAP-1 monoclonal antibody; Fully human anti-vascular adhesion protein 1 monoclonal antibody; SI-3106

Latest Information Update: 09 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotie Therapies Corp.
  • Developer Acorda Therapeutics; Biotie Therapies Corp.; Seikagaku Corporation
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Inflammation; Plaque psoriasis; Primary sclerosing cholangitis; Rheumatoid arthritis

Most Recent Events

  • 28 Feb 2020 Timolumab is available for licensing as of 28 Feb 2020 www.acorda.com
  • 28 Feb 2020 Discontinued - Phase-I for Inflammation (In volunteers) in United Kingdom (IV)
  • 28 Feb 2020 Discontinued - Phase-I for Plaque psoriasis in Germany (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top